Stockscreener 앱 받기
1.80
0.55%
-0.01
전일 마감가:
$1.81
열려 있는:
$1.78
하루 거래량:
1.97M
Relative Volume:
1.49
시가총액:
$162.99M
수익:
$34.48M
순이익/손실:
$-102.07M
주가수익비율:
-0.989
EPS:
-1.82
순현금흐름:
$-104.90M
1주 성능:
-5.76%
1개월 성능:
-8.16%
6개월 성능:
+4.65%
1년 성능:
-69.39%
1일 변동 폭
$1.755
$1.86
1주일 범위
$1.72
$1.97
52주 변동 폭
$1.50
$8.33
Caribou Biosciences Inc Stock (CRBU) Company Profile
명칭
Caribou Biosciences Inc
전화
510-982-6030
주소
2929 7TH STREET, SUITE 105, BERKELEY
CRBU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.80 | 162.99M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 개시 | Evercore ISI | Outperform |
| 2023-07-11 | 개시 | Truist | Buy |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-11-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-17 | 개시 | BofA Securities | Buy |
| 2021-08-17 | 개시 | Citigroup | Neutral |
| 2021-08-17 | 개시 | SVB Leerink | Outperform |
모두보기
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
Caribou Biosciences, Inc. (NASDAQ:CRBU) Position Boosted by Charles Schwab Investment Management Inc. - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 16.2% in November - MarketBeat
Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
Caribou Biosciences' SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com Australia
Caribou Biosciences price target lowered to $6 from $30 at Citi - MSN
Caribou Biosciences Reports Q3 2024 Financial Results - TipRanks
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences CEO to Present at Major Healthcare Conferences on CRISPR Advances | CRBU Stock News - StockTitan
The Rosen Law Firm, P.A. Announces Proposed Class Action - GlobeNewswire
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc. – CRBU - GlobeNewswire Inc.
Steven Cohen's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com
Caribou Biosciences (NASDAQ:CRBU) Receives Buy Rating from HC Wainwright - MarketBeat
PFM Health Sciences, LP Increases Stake in Caribou Biosciences I - GuruFocus.com
Caribou Biosciences' SWOT analysis: biotech stock's potential amid clinical trials - Investing.com Australia
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates - MSN
Brokers Set Expectations for CRBU FY2024 Earnings - Defense World
Leerink Partnrs Issues Optimistic Forecast for CRBU Earnings - Defense World
What is Leerink Partnrs' Forecast for CRBU FY2024 Earnings? - MarketBeat
CRBU FY2024 EPS Increased by Brookline Capital Management - MarketBeat
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) Announces Quarterly Earnings Results - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World
Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Caribou Biosciences earnings beat by $0.07, revenue fell short of estimates - Investing.com UK
Caribou Biosciences reports Q3 EPS (38c), consensus (45c) - TipRanks
CRISPR Technology Market Report 2024, with Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and MoreResearchAndMarkets.com | FinancialContent Business Page - Financial Content
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry - Simply Wall St
Vanguard Group Inc's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com
Critical Analysis: Caribou Biosciences (NASDAQ:CRBU) & Titan Pharmaceuticals (NASDAQ:TTNP) - Defense World
Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? - Insider Monkey
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by Exchange Traded Concepts LLC - Defense World
STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc - GuruFocus.com
Following a 49% decline over last year, recent gains may please Caribou Biosciences, Inc. (NASDAQ:CRBU) institutional owners - Simply Wall St
Its Stock Has Paid Off Big Time For Caribou Biosciences Inc - SETE News
How to interpret Caribou Biosciences Inc (CRBU)’s stock chart patterns - US Post News
Daily Market Movement: Caribou Biosciences Inc (CRBU) Sees a 5.56 Increase, Closing at 1.90 - The Dwinnex
Dimensional Fund Advisors LP Has $4.30 Million Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - MarketBeat
A better buy-in window may exist right now for Caribou Biosciences Inc (CRBU) - SETE News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Purchased by Green Alpha Advisors LLC - Defense World
Caribou Biosciences Inc (CRBU) presents a great opportunity, but the stock is slightly undervalued - US Post News
Analyzing Ratios: Caribou Biosciences Inc (CRBU)’s Financial Story Unveiled - The Dwinnex
Susquehanna Fundamental Investments LLC Sells 91,637 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences Inc (CRBU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):